The company is establishing commercial production capabilities to fuel plans to launch autologous CAR-T cell therapies in China.
British pharma major AstraZeneca (LSE: AZN) is stepping up its China strategy with plans to build a commercial cell therapy manufacturing and supply base in Shanghai, alongside a new innovation center ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results